Neuroendocrine tumors (NETs) are one of the rare cancers that have been increasing in recent years. The importance of Ga-68 DOTA-Conjugated Peptides Receptor imaging has been reported in many retrospective and prospective studies in the diagnosis and clinical management of NETs. Three different somatostatin analogues labeled Ga-68 are used in clinical practice. The most commonly used Ga-68 DOTA-Conjugated Peptides are DOTA-D-Phe-Tyr3-octreotide (DOTA-TOC), DOTA-1-NaI (3)- octreotide (DOTA-NOC) and DOTA-D-Phe-Tyr3-octreotate (DOTA-TATE) in rutin. Although all these radiopeptides bind to sst-r 2, each has different affinity profiles for other sst-r subtypes. Performed related studies have shown that the compound with the highest affinity for somatostatin receptor 2 (sst-r 2), which is most frequently expressed in NETs, is DOTA-TATE. Ga-68 DOTA-bound somatostatin receptor (sst-r) PET/CT is used in the preoperative staging of NETs, determination of treatment response, restaging, showing somatostatin receptor uptake before peptide receptor radionuclide treatment. This guideline, mainly for nuclear medicine physicians contains recommendations in terms of procedure, reporting and interpretation in order to standardize Ga-68 DOTA conjugated peptid PET/CT imaging in NETs.